C臂直线加速器连续床旋转非共面VMAT的质量保证
本研究利用TrueBeam开发模式对连续床旋转非共面容积调强弧形治疗(CCR-VMAT)进行质量保证,在C形模体和五例前列腺癌患者中计划并实施七条无碰撞轨迹。Winston-Lutz测试显示二维平均绝对误差为0.3±0.3毫米,轨迹日志中机架、床和MLC位置误差均很小。床角和MLC位置偏差随速度增加而显著增大,但剂量学精度较高且在不同轨迹间表现稳定。
要点
- CCR-VMAT在TrueBeam开发模式下几何和机械精度高。
- 床角和MLC位置偏差随速度增加而显著增大。
- 剂量学精度较高,3%/3mm伽马通过率均值98.1%。
核心结论
- 通过TrueBeam开发模式实施的CCR-VMAT具有高水平的几何和机械精度,从而提供高剂量学精度。
- CCR-VMAT性能在不同轨迹选择下保持稳定。
研究设计与样本
- 使用TrueBeam开发模式计划和实施CCR-VMAT,针对C形模体和五例前列腺癌患者设计七条无碰撞轨迹,使用RayStation 4.7软件。
- 通过Winston-Lutz测试和轨迹日志计算平均绝对误差(MAE),并评估机械参数与MAE的相关性,使用ArcCHECK评估剂量学精度。
主要发现
- Winston-Lutz测试所有轨迹二维MAE为0.3±0.3毫米。
- 轨迹日志中机架、床和MLC位置的MAE分别 within 0.04°、0.08°和0.02毫米。
- 床角偏差(r=0.98,p<0.05)和MLC位置偏差(r=0.86,p<0.05)随速度增加而显著增大。
- 束流输出误差MAE小于0.01 MU。
- 3%/3mm、3%/1mm和5%/1mm的伽马通过率均值±2SD(范围)分别为98.1±1.9%(95.7-99.6%)、87.2±2.8%(80.2-96.7%)和96.3±2.8%(93.9-99.6%)。
关键数值与推荐
- Winston-Lutz测试二维MAE为0.3±0.3毫米。
- 机架、床和MLC位置MAE分别 within 0.04°、0.08°和0.02毫米。
- 床角偏差与速度相关系数r=0.98(p<0.05),MLC位置偏差与速度相关系数r=0.86(p<0.05)。
- 束流输出误差MAE小于0.01 MU。
- 伽马通过率:3%/3mm为98.1±1.9%(95.7-99.6%),3%/1mm为87.2±2.8%(80.2-96.7%),5%/1mm为96.3±2.8%(93.9-99.6%)。
临床怎么用
- CCR-VMAT可通过TrueBeam开发模式实施,需进行Winston-Lutz测试和轨迹日志验证机械精度。
- 床角和MLC位置偏差随速度增加而增大,临床中需关注速度对精度的影响。
- 使用ArcCHECK等设备进行剂量学验证,确保伽马通过率在可接受范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To perform quality assurance of non-coplanar, volumetric-modulated arc therapy featuring continuous couch rotation (CCR-VMAT) using a C-arm linear accelerator. METHODS: We planned and delivered CCR-VMAT using the TrueBeam Developer Mode. Treatment plans were created for both a C-shaped phantom and five prostate cancer patients using seven CCR trajectories that lacked collisions; we used RayStation software (ver. 4.7) to this end. Subsequently, verification plans were generated. The mean absolute error (MAE) between the center of an MV-imaged steel ball and the radiation field was calculated using the Winston-Lutz test. The MAEs between planned and actual irradiation values were also calculated from trajectory logs. In addition, correlation coefficients (r values) among the MAEs of gantry angle, couch angle, and multi-leaf collimator (MLC) position, and mechanical parameters including gantry speed, couch speed, MLC speed, and beam output, were estimated. The dosimetric accuracies of planned and measured values were also assessed using ArcCHECK. RESULTS: The MAEs ±2 standard deviations as revealed by the Winston-Lutz test for all trajectories were 0.3 ± 0.3 mm in two dimensions. The MAEs of the gantry, couch, and MLC positions calculated from all trajectory logs were within 0.04°, 0.08°, and 0.02 mm, respectively. Deviations in the couch angle (r = 0.98, p < 0.05) and MLC position (r = 0.86, p < 0.05) increased significantly with speed. The MAE of the beam output error was less than 0.01 MU. The mean gamma passing rate ± 2 SD (range) of the 3%/3 mm, 3%/1 mm, and 5%/1 mm was 98.1 ± 1.9% (95.7-99.6%), 87.2 ± 2.8% (80.2-96.7%), and 96.3 ± 2.8% (93.9-99.6%), respectively. CONCLUSIONS: CCR-VMAT delivered via the TrueBeam Developer Mode was associated with high-level geometric and mechanical accuracy, thus affording to high dosimetric accuracy. The CCR-VMAT performance was stable regardless of the trajectory chosen.
引用
- Hirashima H, Nakamura M, Miyabe Y, et al. Quality assurance of non-coplanar, volumetric-modulated arc therapy employing a C-arm linear accelerator, featuring continuous patient couch rotation. Radiat Oncol. 2019. PMID: 30971273. doi:10.1186/s13014-019-1264-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。